Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of ABI-007 for Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed gastric adenocarcinoma~* Received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence~* Age: 20 - 74~* At least one measurable lesion by RECIST criteria~Exclusion Criteria:~* History of Taxans use~* Patients with another active malignancy~* Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE)~* Chronic treatment with steroids

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ABI-007

Based on this trial design, predict the completion outcome and termination type (if applicable).